-
Mashup Score: 0
TUESDAY, Oct. 17, 2023 (HealthDay News) — Americans born in recent years can likely count on taking prescription drugs for about half their life, according to new research.For males born in 2019, it’s about 48% of their lives. For women, it’s 60% of their lifetime, the study found.“The years that p…
Source: consumer.healthday.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 16A new era in the treatment of urothelial carcinoma - 1 year(s) ago
The advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in tr…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists1Tweet-
RT @FaltasLab: 📘 Honored to guest edit this @UrolOncol Special Issue on advances in UC treatments ➡️ https://t.co/boHwK4MIaV Featuring arti…
-
-
Mashup Score: 1Engineering Multimodal Immunotherapies against Small-Cell Neuroendocrine Tumors | The Mark Foundation for Cancer Research - 1 year(s) ago
Small-cell neuroendocrine tumors (SCNTs) represent an aggressive group of difficult-to-treat tumors with shared characteristics that pose significant challenges in patient care.
Source: themarkfoundation.orgCategories: Latest Headlines, Oncologists1Tweet-
Congratulations to #lungcancer friend + colleagues @SageJulien + amazing team for their new @TheMarkFdn award to study novel immunotherapy regimens in SCLC! #LCSM https://t.co/YeVkJApIwP
-
-
Mashup Score: 2The Internal Mammary Node Irradiation Debate in Node-Positive Breast Cancer: Case Closed - 1 year(s) ago
This month’s Oncology Scan focuses on 3 recent studies that examined internal mammary node (IMN) irradiation (IMNI) and offers our perspective on their applicability to clinical practice. The IMNI debate continues due to a couple of key issues. First, until recently, there was only 1 negative randomized clinical trial of IMNI versus no IMNI demonstrating no improvement in 10-year overall survival (OS).1 This study began over 30 years ago, and the final report was issued a decade ago, but this negative trial has allowed the IMNI debate to persist.
Source: www.redjournal.orgCategories: Latest Headlines, Oncologists1Tweet-
Hey #radonc "case closed" on IMN XRT for breast?! https://t.co/FM3Dh43xmC Hogwash😂 1) R br Ca does better https://t.co/otjgKtOAcc https://t.co/YPEEudYhxA 2) IMN XRT not proven https://t.co/J5Eoytogkt 3) A trial w/ some IMN XRT shows no OS imprvmt https://t.co/w6ijPxd589
-
-
Mashup Score: 2
What are Cookies?A cookie is a small text-based file placed on your device after you visit a website. We use different types of cookies to: Help us learn more about how people use our websites, so we can make our sites more useful Deliver content that is meaningful to your while you are on our website. Deliver advertising about Ohio State to your after you leave our website. Discover…
Source: buildingthefuture.osu.eduCategories: Latest Headlines, Oncologists1Tweet-
The@PelotoniaResearch Center is going to bring countless scientific innovations to the world, including breakthroughs in #cancer care from the @OhioStatePIIO and our Center for Cancer Engineering. https://t.co/8pYJqKxTRF
-
-
Mashup Score: 1
Roche is forging a new partnership with a startup focused on protein degradation. The multinational pharma company announced Tuesday it is paying $50 million upfront to team up with Monte Rosa Therapeutics and its slate of “molecular glue” programs that it argues can target proteins central to the degradation process.
Source: endpts.comCategories: Latest Headlines, Oncologists1Tweet-
RT @endpts: Roche is forging a new partnership with a startup focused on protein degradation. $GLUE https://t.co/ux16Qj6fAJ
-
-
Mashup Score: 0Stanford joins multi-institutional team developing pioneering immunotherapy technology - 1 year(s) ago
Stanford is part of a multi-institutional team to develop an implantable device capable of providing both continuous immunotherapy treatment and real-time monitoring of patients with peritoneal cancers.
Source: med.stanford.eduCategories: Latest Headlines, Oncologists1Tweet-
Congratulations to SCI member @RetickerFlynn and Omid Veish of @Rice_BIOE for receiving a @ARPA_H grant for a project entitled Targeted hybrid oncotherapeutic regulation (THOR). https://t.co/HYEgWjZcNm #OvarianCancer
-
-
Mashup Score: 1
Das Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg vereinigt Patientenversorgung, Krebsforschung und Krebsprävention unter einem Dach, um alle für den Kampf gegen Krebs relevanten Aspekte zu berücksichtigen.
Source: www.nct-heidelberg.deCategories: Latest Headlines, Oncologists1Tweet-
At #DGHO2023 @dgho_eV Julia König presented first results of our ELABORATE project, in which we investigate economic influence on cancer medicine. More information about ELABORATE at: https://t.co/RbLoeoWiST https://t.co/VP37pvsbKH
-
-
Mashup Score: 0
Das Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg vereinigt Patientenversorgung, Krebsforschung und Krebsprävention unter einem Dach, um alle für den Kampf gegen Krebs relevanten Aspekte zu berücksichtigen.
Source: www.nct-heidelberg.deCategories: Latest Headlines, Oncologists1Tweet-
At #DGHO2023 @dgho_eV Julia König presents first results of our ELABORATE project, in which we investigate economic factors influencing doctors’ medical decisions-making. More information about ELABORATE at: https://t.co/RbLoeoWiST https://t.co/GtqtYvrwAz
-
-
Mashup Score: 0The Burden of Lung Cancer in Women Compared With Men in the US - 1 year(s) ago
This cross-sectional study examines the incidence rates of lung cancer in women compared with men from 2000 to 2019.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists1Tweet-
ICYMI: Lung cancer in women. @UTSWIMchief @UTSWInternalMed @UTSWHemeOnc @utswcancer https://t.co/WZzmipLfVO
-
“The desire to take medicine is perhaps the greatest feature which distinguishes man from animals.” - Sir William Osler. #Oncology #BCSM #LCSM #BTSM #GynCSM #MedOnc #RadOnc #Urology #GynOnc #Cancer #PanCan #PCSM https://t.co/dznbqJNnrz